Initial Response to Therapy with Fulvestrant and Cyclin-Dependent Kinase 4/6 Inhibitor in a Male with Stage IV Breast Cancer

Memorial Cancer Institute, Breast Center, Florida, USA.

Corresponding Author: Aurelio B. Castrellon, Memorial Healthcare System, Memorial Cancer Institute, Breast Center, Director of Breast Cancer Research, Florida USA, Tel: (954) 265-4325; E-Mail: [email protected]

Received Date: 21 Feb 2017   
Accepted Date: 27 Feb 2017    
Published Date: 01 Mar 2017

Copyright © 2017 Castrellon AB

Citation: Castrellon AB, Nguyen SM, Milillo Naraine AM, Velez M, et al. (2017). Initial Response to Therapy with Fulvestrant and Cyclin-Dependent Kinase 4/6 Inhibitor in a Male with Stage IV Breast Cancer. Mathews J Cancer Sci. 2(1): 012.

ABSTRACT

Male breast cancer (MaBC) accounts for less than 1% of breast cancers (BC). Based on the low incidence of MaBC, information from randomized clinical trials is not available. Therefore, the same guidelines for palliative endocrine therapy in women with advanced BC are generally followed for men. Endocrine therapy (ET) represents the first line of treatment for male patients with stage IV disease in the absence of a visceral crisis. However, resistance to ET in hormone receptor positive advanced breast cancer is common, and given sufficient time, most patients are faced with disease progression. In this report we describe the case of a male that experienced systemic recurrence of BC following adjuvant therapy for locally advanced disease. First line endocrine treatment was combined with a cyclin-dependent kinase 4/6 inhibitor, leading to a dramatic radiographic and clinical response.